|Mr. David B. Seaburg||Chief Exec. Officer||680.07k||N/A||1970|
|Mr. Richard Hague||Pres & COO||649.26k||N/A||1960|
|Mr. Cameron J. Hoyler||Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy||623.19k||N/A||1984|
|Mr. Jacob Alexander Patterson||Interim Chief Financial Officer||N/A||N/A||1979|
|Mr. Nikolai Sopko||Chief Scientific Officer and VP of R&D||N/A||N/A||N/A|
|Mr. Rich Haerle||VP of Investor Relations & Strategy||N/A||N/A||N/A|
|Angela Ziegler||VP of Marketing & PR||N/A||N/A||N/A|
|Mr. Alain Adam||VP of Sales||N/A||N/A||N/A|
|Dr. Edward Winslow Swanson||Chief Medical Officer & Co-Founder||N/A||N/A||1985|
|Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS||Chief Clinical Officer & Member of Clinical Advisory Board||N/A||N/A||1949|
PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and OsteoTE. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
PolarityTE, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.